

# Patient - PACT

## New Clinical Trial and Research



Trial title	A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
Trial synopsis	This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).
Investigational medicinal product	PRM-151 or placebo
Disease target	Idiopathic pulmonary fibrosis
Sponsor	F. Hoffmann-La Roche Ltd
Duration	Start (ANZ): April-2021 to March-2023 Participants will receive intravenous (IV) infusions of PRM-151 or placebo over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
Trial Status	Recruiting
Lead site(s) in Australia	Lung Research Queensland (private sites) and Princess Alexandra Hospital (public sites)
Lead site(s) in New Zealand	University of Otago, Christchurch
Additional sites	<p>AUSTRALIA</p> <ul style="list-style-type: none"> <li>• WA Fiona Stanley Hospital, Michael Musk</li> <li>• VIC Monash Medical Centre Clayton, Xun Li</li> <li>• NSW Royal Prince Alfred Hospital, Tamera Corte</li> <li>• QLD Lung Research Queensland, Dan Chambers</li> <li>• VIC The Alfred Hospital, Ian Glaspole</li> <li>• QLD Princess Alexandra Hospital, Gregory Keir</li> <li>• Cairns Hospital QLD PI: Dr James Brown</li> </ul> <p>NEW ZEALAND</p> <ul style="list-style-type: none"> <li>• Tauranga Hospital, Suzanne Poole</li> <li>• NZ Respiratory and Sleep Institute, Andrew Veale</li> <li>• Auckland City Hospital, Margaret Wilsher</li> <li>• Waikato Hospital, Catherina Chang</li> <li>• Research and Enterprise University of Otago, Lutz Beckert</li> </ul>
Contact	pactcoordinator@cre-pf.org.au